Fungal Infection News and Research

RSS

New UK national genome centre

A new UK national genome centre was officially opened by Nobel Laureate and genome pioneer Prof Sir John Sulston and the Lord-Lieutenant of Norfolk.

5 Jul 2009

Researchers discover six new genome sequences and fundamental insights to the Candida fungus family

An international research collaboration coordinated by UCD researchers and involving scientists at 21 institutes including the genome sequencing centres in the Wellcome Trust Sanger Institute, UK and the Broad Institute at MIT and Harvard, USA have defined six new genome sequences in the Candida fungus family and identified genetic differences in species that cause disease.

25 May 2009

Cimzia approved in U.S. for rheumatoid arthritis

UCB announced today that the U.S. Food and Drug Administration (FDA) approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

13 May 2009

New test for a deadly fungal infection in patients with damaged immune systems

A quicker, cheaper and more accurate test for deadly Aspergillus fumigatus fungal infections in patients with damaged or suppressed immune systems was described today, (Thursday 2 April) at the Society for General Microbiology meeting in Harrogate, by Dr Christopher Thornton from the University of Exeter, UK.

1 Apr 2009

Sirion Therapeutics sNDA for Durezol to treat uveitis accepted for FDA review

Sirion Therapeutics, Inc. announced today that its supplemental New Drug Application (sNDA) submitted to the U.S. Food and Drug Administration (FDA) seeking market approval of Durezol(TM) (difluprednate ophthalmic emulsion) 0.05% to treat endogenous anterior uveitis has been accepted for review.

16 Mar 2009

Zoologists search sea for drugs of the future

No matter how sophisticated modern medicine becomes, common ailments like fungal infections can outrun the best of the world's antibiotics.

26 Feb 2009

Toenail clippings reveal environmental arsenic exposure

Scientists from Leicester and Nottingham have devised a method for identifying levels of exposure to environmental arsenic - by testing toenail clippings.

22 Feb 2009

Antifungal medication could provide asthma relief for 150,000 UK sufferers

Up to 150,000 people suffering from severe asthma in the UK could benefit from taking antifungal medication already available from pharmacists, new research has found.

From The University of Manchester 30 Dec 2008

Voriconazole effective in combating fungal infections

The effectiveness of voriconazole in combating fungal infections has been confirmed by a new study to be featured in the International Journal of Antimicrobial Agents, published by Elsevier.

16 Dec 2008

RHEI Pharmaceuticals starts final trial of Tibozole in China

RHEI Pharmaceuticals, Inc. has announced that the final clinical trial for Tibozole, a locally active antifungal with low dose miconazole in a patented mucoadhesive system, has been initiated in China.

8 Dec 2008

Swiss approval for Zevtera in treatment of complicated skin and soft tissue infections

Swissmedic, the Swiss agency for therapeutic products, has approved Zevtera (ceftobiprole medocaril) for the treatment of complicated skin and soft tissue infections, including diabetic foot infections which have not spread to the bone.

13 Nov 2008

NanoBio demonstrates new topical approach to treating nail fungus that circumvents problems with current therapy

A novel topical therapy for nail fungus, NB-002, has demonstrated a new topical approach to healing nail fungus by penetrating skin pores and diffusing through the skin that surrounds the entire nail plate, according to a study conducted by NanoBio Corporation.

27 Oct 2008

New technology promises tests for diseases such as cancer in 15 minutes

Scientists at Leeds University in the UK say soon, testing for diseases such as cancer and multiple sclerosis, could take as little as 15 minutes and could be as simple as using a pregnancy testing kit.

1 Oct 2008

FDA forces manufacturers of TNF-blockers to highlight risk of fungal infections

The U.S. Food and Drug Administration today announced that the manufacturers of Humira, Cimzia, Enbrel, and Remicade must strengthen the existing warnings, in the Warnings and Precaution sections of the drugs' prescribing information and Medication Guides, on the risk of developing opportunistic fungal infections. Some patients with invasive fungal infections have died.

5 Sep 2008

Doctors should consider alternatives to antibiotics for sinusitis

When suffering through a sinus infection, many people ask for an antibiotic to speed their recovery. However, a recent review of clinical trials found that while antibiotics can provide minor improvements in uncomplicated sinusitis cases, most patients recover without the drugs within two weeks.

24 Apr 2008

Researchers battle against dangerous corn toxin

The spiraling use of corn for food and fuel is creating heightened concerns about contamination of this staple crop with deadly aflatoxin.

9 Apr 2008

NanoBio completes interim analysis of phase 2 clinical trial in onychomycosis

NanoBio Corporation has announced that it has seen promising results from an interim analysis of its phase 2 study of NB-002, a topical lotion for onychomycosis (nail fungus). Although the details remain confidential, the results clearly justify completing the study, according to NanoBio scientists

24 Mar 2008

New understanding of rare immune disorder called Job's syndrome

Scientists have made another major breakthrough--the second in the past year--in understanding a rare immune disorder called Job's syndrome.

18 Mar 2008

Risk factors for severe RSV infection in immunocompromised children

St. Jude Children's Research Hospital investigators and collaborators have shown how to predict if a child who is infected with respiratory syncytial virus (RSV) while being treated for cancer or another catastrophic disease is at high risk for developing severe infection. The finding will help clinicians improve guidelines for managing these infected children.

4 Feb 2008

FDA approves only once-daily inhaled corticosteroid for children

Schering-Plough Corporation has announced that the U.S. Food and Drug Administration (FDA) has approved ASMANEX TWISTHALER 110 mcg (mometasone furoate inhalation powder) for the maintenance treatment of asthma as a preventive therapy in patients 4 to 11 years of age.

4 Feb 2008